These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2888738)

  • 1. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
    Morgan MY; Stambuk D
    Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers.
    Gao S; Liu GL; Wang SX; Gao XH
    Zhongguo Yao Li Xue Bao; 1991 May; 12(3):195-8. PubMed ID: 1781278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ebrotidine in rats and dogs.
    Albet C; Pérez JA; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose.
    Bologna M; Napolitano T; Biordi L; Carlucci G
    Drugs Exp Clin Res; 1988; 14(6):419-21. PubMed ID: 2905638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of plasma, urine and gastric juice concentrations of famotidine using high performance liquid chromatography.
    Bologna M; Biordi L; Napolitano T; Carlucci G
    Int J Clin Pharmacol Res; 1988; 8(5):335-40. PubMed ID: 3229873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
    Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
    Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
    Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man.
    Necciari J; Mery D; Garriot P; Escourrou J; Cautreels W
    Int J Clin Pharmacol Res; 1985; 5(6):457-65. PubMed ID: 2869002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nizatidine, an H2-blocker. Its metabolism and disposition in man.
    Knadler MP; Bergstrom RF; Callaghan JT; Rubin A
    Drug Metab Dispos; 1986; 14(2):175-82. PubMed ID: 2870891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
    Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.
    Täuber U; Haack D; Nieuweboer B; Kloss G; Vecsei P; Wendt H
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):48-55. PubMed ID: 6698661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
    Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
    Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
    Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
    Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of pidotimod in rats and dogs.
    Coppi G; Silingardi S
    Arzneimittelforschung; 1994 Dec; 44(12A):1460-4. PubMed ID: 7857342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.